-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 6, 2022 /Bio Valley BIOON/ --Recently, in a research report titled "Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies" published in the international journal Nature Communications, from Scientists in the Netherlands have found that blocking a protein chain reaction may make childhood leukemia cells more sensitive to current targeted therapies; the research is still in the early stages, but the drugs used in the study already exist, which It is expected to help accelerate the speed of translation of this research into the clinic; the researchers say that observing the activity of this protein may help to fully understand the weaknesses of leukemia, and in the future, researchers will develop new treatments to treat children with the disease who do not respond to standard treatments.
Image Credit: Unsplash/CC0 Public Domain
For one in five children with T-cell acute lymphoblastic leukemia (T-ALL), the disease relapses after therapy, and in many cases current high-dose chemotherapy has stopped working, so researchers New approaches are urgently needed to address this disease
In this study, the researchers deeply analyzed all the active proteins in T-ALL cells in the laboratory.
By analyzing all of the protein switches from 11 different types of T-ALL cells, the researchers identified a variety of proteins known to be associated with the disease, including two called LCK and SRC, as well as a protein called LCK and SRC.
Image source: https:// further investigate the efficacy of this drug combination, the researchers looked at the effects of leukemia cells from T-ALL leukemia mice grown in mice, in which SRC proteins and INSR/IGR-1R chain reaction activity were significantly higher In cells with high ALL, the drug combination was again very effective, and the genes encoding these proteins did not fail in any way, which may suggest that the activity of the protein may be a very valuable route in the search for drug targets for the treatment of ALL.
When exploring potential new ways to attack leukemia, it's important to understand the big picture of the weaknesses in these cells, says Cordo, the researcher.
Original source:
Cordo', V.
